Surgery

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

The company plans on launching VIA360 immediately in the US market.

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when compared to the year prior.

Real-world scenarios showcase a shift in treatment paradigms

From easing fears to improving mood, a recent study explores how music transforms the surgical experience for both patients and health care teams.

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

As Ophthalmology Times celebrates 50 years of publication and the Wilmer Eye Institute marks 100 years of academic leadership, Peter J. McDonnell, MD, reflects on their shared commitment to helping ophthalmologists improve patient outcomes.

Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.

Glaucoma specialists discuss pairing patients with the right procedures.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

A team of Bascom Palmer Eye Institute and University of Miami researchers have received an award to fund the procurement, preservation, and transplantation of a human eye to restore vision.

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s high rate of avoidable blindness. Trainees gain proficiency through simulation-based learning and live surgeries, improving access to eye care in remote areas.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Custom-designed, lens-based surgery is a less interventional surgical option.

A Norwegian study demonstrates that transplant rates continue to drop over time

Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.